Affordable Access

Publisher Website

Ocular Inflammation and Infection

International Journal of Inflammation
Hindawi Limited
Publication Date
DOI: 10.1155/2012/403520
  • Editorial
  • Medicine


Hindawi Publishing Corporation International Journal of Inflammation Volume 2012, Article ID 403520, 2 pages doi:10.1155/2012/403520 Editorial Ocular Inflammation and Infection Michelle Callegan,1 Meredith Gregory-Ksander,2 Mark Willcox,3 and Susan Lightman4 1Department of Ophthalmology, University of Oklahoma Health Sciences Center and Dean McGee Eye Institute, Oklahoma City, OK 73104, USA 2Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Harvard Mechanical school, Boston, MA 02114, USA 3School of Optometry and Vision Science, University of New South Wales, Sydney, NSW 2052, Australia 4Moorfields Eye Hospital NHS Foundation Trust, London EC 1V 2PD, UK Correspondence should be addressed to Michelle Callegan, [email protected] Received 15 August 2012; Accepted 15 August 2012 Copyright © 2012 Michelle Callegan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The eye is a unique and necessary organ that is constantly exposed to the environment. In an immune-privileged envi- ronment such as the eye, a delicate balance exists between immune responses that limit damage and those responses that can result in irreversible damage. Ocular inflammation and infection are therefore potentially blinding events. Efforts to analyze the delicate balance between helpful and harmful immune responses in the eye have involved a variety of animal studies and models which analyze not only the specific etiologic agents of infection and the contributions of their products in inflammation and vision loss but also the underlying host factors responsible for those responses. Other studies have probed the development of novel therapeutics based on endogenous host factors as well as pathogen-specific targets and have tested these with routinely used therapeutics in improved regimens in an effo

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times